NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

Author:

Griffiths Elizabeth A.1,Roy Vivek2,Alwan Laura3,Bachiashvili Kimo4,Baird John5,Cool Rita6,Dinner Shira7,Geyer Mark8,Glaspy John9,Gojo Ivana10,Hicks Ashley11,Kallam Avyakta12,Kidwai Wajih Zaheer13,Kloth Dwight D.14,Kraut Eric H.15,Landsburg Daniel16,Lyman Gary H.3,Mahajan Anjlee17,Miller Ryan18,Nachar Victoria19,Patel Seema20,Patel Shiven21,Perez Lia E.22,Poust Adam23,Riaz Fauzia24,Rosovsky Rachel25,Rugo Hope S.26,Simon Shayna27,Vasu Sumithira15,Wadleigh Martha28,Westbrook Kelly29,Westervelt Peter30,Berardi Ryan A.31,Pluchino Lenora31

Affiliation:

1. 1Roswell Park Comprehensive Cancer Center;

2. 2Mayo Clinic Cancer Center;

3. 3Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

4. 4O'Neal Comprehensive Cancer Center at UAB;

5. 5City of Hope National Medical Center;

6. 6The University of Texas MD Anderson Cancer Center;

7. 7Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

8. 8Memorial Sloan Kettering Cancer Center;

9. 9UCLA Jonsson Comprehensive Cancer Center;

10. 10The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

11. 11University of Wisconsin Carbone Cancer Center;

12. 12Fred & Pamela Buffett Cancer Center;

13. 13Yale Cancer Center/Smilow Cancer Hospital;

14. 14Fox Chase Cancer Center;

15. 15The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

16. 16Abramson Cancer Center at the University of Pennsylvania;

17. 17UC Davis Comprehensive Cancer Center;

18. 18Vanderbilt-Ingram Cancer Center;

19. 19University of Michigan Rogel Cancer Center;

20. 20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

21. 21Huntsman Cancer Institute at the University of Utah;

22. 22Moffitt Cancer Center;

23. 23University of Colorado Cancer Center;

24. 24Stanford Cancer Institute;

25. 25Massachusetts General Hospital Cancer Center;

26. 26UCSF Helen Diller Family Comprehensive Cancer Center;

27. 27UT Southwestern Simmons Comprehensive Cancer Center;

28. 28Dana-Farber/Brigham and Women's Cancer Center;

29. 29Duke Cancer Institute;

30. 30Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; and

31. 31National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

Publisher

Harborside Press, LLC

Subject

Oncology

Reference32 articles.

1. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours;Zhang;Cochrane Database Syst Rev,2017

2. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia;Miao;Am J Hematol,2018

3. Romiplostim treatment of chemotherapy-induced thrombocytopenia;Soff;J Clin Oncol,2019

4. Romiplostim for management of chemotherapy-induced thrombocytopenia;Parameswaran;Support Care Cancer,2014

5. Safety and efficacy of eltrombopag and romiplostim in myelodysplastic syndromes: a systematic review and meta-analysis;Meng;Front Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3